Protein / target
Pancreatic triacylglycerol lipase
Protein at a glance
Biological role
Glycerophospholipid phospholipase A1 activity
Primary system
Endocrine & metabolic
Strongest disease association
pancreatic triacylglycerol lipase deficiency
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
2 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Plays an important role in fat metabolism. It preferentially splits the esters of long-chain fatty acids at positions 1 and 3, producing mainly 2-monoacylglycerol and free fatty acids, and shows considerably higher activity against insoluble emulsified substrates than against soluble ones
Subcellular location
Domains and Gene Ontology detail (15)Hide
Domains & features
Gene Ontology
- Cextracellular region
- Cextracellular space
- Fall-trans-retinyl-palmitate hydrolase, all-trans-retinol forming activity
- Fglycerophospholipid phospholipase A1 activity
- Flipase activity
- Flipoprotein lipase activity
- Fmetal ion binding
- Ftriacylglycerol lipase activity
- Pcholesterol homeostasis
- Pfatty acid biosynthetic process
- Phigh-density lipoprotein particle remodeling
- Plipid metabolic process
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·lipid metabolic process
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Pancreatic lipase inhibitor
Appears in clinical studies involving obesity disorder, Obesity, Infertility, Sleep apnea
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 369 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 2 total
obesity disorder · Obesity · Infertility
Obesity · type 2 diabetes mellitus · inherited lipid metabolism disorder
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- New publicationExploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
- Safety communication
Drug Safety Update: Orlistat: theoretical interaction with antiretroviral HIV medicines
- New publicationA randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss.
- Regulatory approval
Approval: Alli (previously Orlistat GSK) (EMA)
- New publicationEfficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions.
- New publicationThree-month tolerability of orlistat in adolescents with obesity-related comorbid conditions.
- New publicationEffects of orlistat on fat-soluble vitamins in obese adolescents.
- Regulatory approval
Approval: Xenical (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.